 Home > Active Ingredient News > Blood System > Blood: Long-term efficacy of Venetog+Rituximab in the treatment of recurrent CLL

Blood: Long-term efficacy of Venetog+Rituximab in the treatment of recurrent CLL

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

sennosides 8.6 mg tab

vortex 1 10

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chemical immunity after therapy (CIT) treatment therapy early to get the depth of remission, minimal residual disease undetectable (uMRD) progression of chronic lymphocytic leukemia (CLL) patients without further treatment, but also with an extended lifetime (PFS)

immunity

Recently, the Journal of Blood reported the long-term follow-up results of a phase 1b study, which aims to evaluate the efficacy of venetoxer and rituximab (VenR) in patients with recurrent CLL

"Blood" evaluates the efficacy of Venetog and Rituximab (VenR) in patients with recurrent CLL

In this study, the test patients received Venetog (200-600 mg/day) and rituximab after continuous treatment for 6 months, which was maintained as a single agent of Venetog

PFS and OS

A total of 49 patients were recruited, and the median follow-up time was 5.

The 5-year overall survival rate, progression-free survival rate, and duration of remission are 86% (72-94), 56% (40-70), and 58% (40-73) , respectively.

Duration of remission for patients who have achieved remission

The five-year estimate of the sustained remission rate for patients on continuous or limited treatment is similar (71% vs 79%)

The five-year estimate of the sustained remission rate for patients on continuous or limited treatment is similar (71% vs 79%) The five-year estimate of the sustained remission rate for patients on continuous or limited treatment is similar (71% vs 79%) 4 patients VenR treatment was performed, and as of the evaluation date, 3 of them had achieved partial remission

PFS in patients with continuous treatment or limited treatment

In summary, for patients with chronic lymphocytic leukemia, the deep remission induced by the VenR regimen is highly durable regardless of whether the patient continues to be treated or stopped

For patients with chronic lymphocytic leukemia, the deep remission induced by the VenR regimen is highly durable regardless of whether the subsequent patient continues treatment or stops the treatment.

Original source:

Shuo Ma, John F.

Efficacy of venetoclax plus rituximab for relapsed CLL : 5-year follow-up of continuous or limited- duration therapy

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.